Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EDIT vs CGON: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGON Captures Overall Composite Edge (44.5 HOLD vs 51.6 HOLD), While EDIT Leads 5–1 on Growth & Valuation Pillars
CGON Overall Winner
6-Pillar Tally: EDIT 5 – 1 CGON
Matrix Metrics: EDIT 3 – 5 CGON
As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (44.5/100 HOLD vs. 51.6/100 HOLD) after splitting the core matrix 5–3 (led by Options & Positioning), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin).
- Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CGON 44.5/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -167.0% operating margin) and revenue trajectory (-3.7% vs. +37.4% YoY).
- Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About EDIT vs CGON
EDIT
Editas Medicine, Inc. Common Stock
$1.91
-12.21% 1D
Market Cap
$336.5M
TTM Revenue
$50M
Forward P/E
N/M
Beta / 30D Vol
2.32β · 102% Vol
Unified Composite Score
51.6
HOLD
Tech 40.0
Fund 54.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
CGON
Head-to-Head Winner
CG Oncology, Inc. Common stock
$84.94
+14.17% 1D
Market Cap
$6.3B
TTM Revenue
$6.2M
Forward P/E
N/M
Beta / 30D Vol
0.75β · 89% Vol
Unified Composite Score
44.5
HOLD
Tech 15.0
Fund 43.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (EDIT 5 – 1 CGON)
1. Valuation Multiples
EDIT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
5.2x
N/M
2. Growth & Scale
EDIT
Revenue Growth (YoY)
+37.4%
-3.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$50M
$6.2M
Market Cap
$336.5M
$6.3B
3. Profitability & Quality
EDIT
Gross Margin
-73.3%
N/A
Operating Margin
-167.0%
-4293.5%
Net Profit Margin
-144.9%
0.0%
Return on Equity (ROE)
-147.4%
-28.3%
4. Balance Sheet & Cash Flow
EDIT
Cash Generation (TTM)
-$110M
-$189M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$79M Net Cash
$19M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CGON
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
95.8% (38th %ile)
238.6% (85th %ile)
Put/Call OI Skew
0.29x (Call-Skewed)
0.35x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
EDIT
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Concentrated Oligopoly Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EDIT (3) vs CGON (5)| Institutional Metric | EDIT | CGON | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $336.5M | $6.3B | CGON | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +37.4% | -3.7% | EDIT | |
| Operating Margin (TTM) | -167.0% | -4293.5% | EDIT | |
| Net Profit Margin | -144.9% | 0.0% | CGON | |
| Return on Equity (ROE) | -147.4% | -28.3% | CGON | |
| 52-Week Range Position | 11% ($2–$4) | 84% ($37–$94) | CGON | |
| Beta / 30D Volatility | 2.32β · 102% Vol | 0.75β · 89% Vol | CGON | |
| Unified Institutional Score | 51.6 / 100 (HOLD) | 44.5 / 100 (HOLD) | EDIT | |
| Trailing 12M Revenue (USD) | $50M | $6.2M | Scale | |
| Gross Profit Margin (TTM) | -73.3% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 5.2x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$110M ($79M Net Cash) | -$189M ($19M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGON +60.87 pp
3M Horizon
CGON +45.19 pp
6M Horizon
CGON +59.68 pp
1Y Horizon
CGON +149.96 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EDIT Revenue | CGON Revenue | EDIT Op. Margin | CGON Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $30M | N/A | -356.1% | N/A | EDIT |
| FY2019 | $20M | N/A | -686.4% | N/A | EDIT |
| FY2020 | $90M | N/A | -148.6% | N/A | EDIT |
| FY2021 | $30M | N/A | -756.1% | N/A | EDIT |
| FY2022 | $20M | N/A | -1146.3% | N/A | EDIT |
| FY2023 | $80M | $0M | -216.6% | -27180.9% | EDIT |
| FY2024 | $30M | $0M | -777.2% | -10067.3% | EDIT |
| FY2025 | $40M | $0M | -394.9% | -4722.1% | EDIT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
EDIT
BREAKDOWN
Current IV
95.8%
IV Percentile
38th %ile
Put/Call OI Skew
0.29x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CGON
CONSOLIDATION
Current IV
238.6%
IV Percentile
85th %ile
Put/Call OI Skew
0.35x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
EDIT Moat Profile
Concentrated Oligopoly Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published · CRISPR / Gene Editing
CGON Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ EDIT vs CGON Key Questions & Quantitative Answers
As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (44.5/100 HOLD vs. 51.6/100 HOLD) after splitting the core matrix 5–3 (led by Options & Positioning), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. CGON 44.5/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -167.0% operating margin) and revenue trajectory (-3.7% vs. +37.4% YoY). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EDIT leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while CGON shifted N/A. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.
EDIT screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus CGON (-28.3% ROE) capital efficiency.
In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 89% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CGON vs EDIT · Reverse Pair
EDIT vs NTLA
· Sector Peer
EDIT vs CRSP
· Sector Peer
EDIT vs BEAM
· Sector Peer
CGON vs AVBP
· Sector Peer
CGON vs SYRE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem